RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers-Reference-Cited by-同舟云学术

RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers

Published:2018-08-13 Issue:9 Volume:20 Page:1064-1073
ISSN:1465-7392
Container-title:Nature Cell Biology
language:en
Short-container-title:Nat Cell Biol

Author:

Nichols Robert J.,Haderk Franziska,Stahlhut Carlos,Schulze Christopher J.,Hemmati Golzar,Wildes David,Tzitzilonis Christos,Mordec Kasia,Marquez Abby,Romero Jason,Hsieh Tientien,Zaman Aubhishek,Olivas Victor,McCoach Caroline,Blakely Collin M.,Wang Zhengping,Kiss Gert,Koltun Elena S.,Gill Adrian L.,Singh Mallika,Goldsmith Mark A.,Smith Jacqueline A. M.^ORCID,Bivona Trever G.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Cell Biology

Link

http://www.nature.com/articles/s41556-018-0169-1.pdf

Reference49 articles.

1. Dhillon, A. S., Hagan, S., Rath, O. & Kolch, W. MAP kinase signalling pathways in cancer. Oncogene 26, 3279–3290 (2007).

2. Bos, J. L., Rehmann, H. & Wittinghofer, A. GEFs and GAPs: critical elements in the control of small G proteins. Cell 130, 385 (2007).

3. The Cancer Genome Atlas Research Network Comprehensive molecular profiling of lung adenocarcinoma. Nature 511, 543–550 (2014).

4. Krauthammer, M. et al. Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas. Nat. Genet. 47, 996–1002 (2015).

5. Redig, A. J. et al. Clinical and molecular characteristics of NF1-mutant lung cancer. Clin. Cancer Res. 22, 3148–3156 (2016).

Cited by 302 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SHANK3 depletion leads to ERK signalling overdose and cell death in KRAS-mutant cancers;Nature Communications;2024-09-12

2. Towards Targeting Endothelial Rap1B to Overcome Vascular Immunosuppression in Cancer;International Journal of Molecular Sciences;2024-09-12

3. Mechanisms of resistance to KRASG12C inhibitors in KRASG12C-mutated non-small cell lung cancer;Frontiers in Oncology;2024-09-05

4. Targeting the RAS upstream and downstream signaling pathway for cancer treatment;European Journal of Pharmacology;2024-09

5. Advances in SHP2 tunnel allosteric inhibitors and bifunctional molecules;European Journal of Medicinal Chemistry;2024-09